Nammude Arogyam Feb 2018 | Page 87
ico-c-¯n D¸m-Zn-¸n
-¡p¶ C³kp-ensâ icn
-bmb {]hÀ¯\w
\S-¡m¯ ImcWw
(C³kp-en³ sdkn-̳kv)
cà-¯nse ]©-km-c
-bpsS Afhv IqSp-Ibpw
AXv aqew IqSp-XÂ
C³kp-en³ D¸m-Zn-¸n
-¡m-\pÅ ktµiw Xe
-t¨m-dn \n¶v ]m³{In-bm
-knsâ _oäm-skÂkn\v
e`n-¡p-Ibpw sN¿p-¶p.
AXv hgn IqSp-XÂ C³kp
-en³ D¸m-Zn-¸n-¡-s¸-Sp
-¶p. CXn-\mWv ""ssl¸À
C³kp-en-t\-anb'' F¶p
]-d-bp-¶-Xv. CXn-\mÂ
`£Ww Ignªv GXm\pw
aWn-¡q-dp-IÄ¡Iw cà
-¯nse ]©-km-c-bpsS
Afhv {Iam-Xo-X-ambn
Ipd-bp¶ AhØ
(sslt¸m ss¥ko-an-b)
Dïm-Ip-¶p. CXv `mhn-bnÂ
{]ta-l-ap-ïm-Im³ km[y
-X-bp-Å-hÀ¡mWv Dïm-Ip
-¶-Xv. GsXm-cm-sfbpw
{]tal ]qÀÆm-h-Ø-bnÂ
Iïp-]n-Sn-¡m-\m-bm ]e
coXn-bnepw {]tal tcmKw
]nSn-s]-Sm-Xn-cn-¡mt\m
AsÃ-¦n {]ta-lm-h-Ø
-bn-te-¡pÅ ]ptcm-K-a-\
-Imew ZoÀLn-¸n-¡mt\m
km[n-¡pw. F¶mÂ
km[m-cW \ne-bnÂ
{]tal ]qÀÆm-h-Ø-bnÂ
hcp-¶-hÀ NnIn-Õn-¡mt\m
thï D]-tZ-i-§Ä kzoI
-cn-¡mt\m hnap-JX Im«p-I
-bmWv sN¿p-¶-Xv.
{]ta-l-am-bn-Ã-tÃm, Bbn«v
NnIn-Õn-¨m t]msc
-sb¶ at\m-`m-h-am-Wv.
F§n-s\-bmWv {]ta-l-]qÀÆm-hØ
Ip-]n-Sn-¡p-¶-Xv
1. FBS (^m-Ìn§v »Uv jpKÀ) >1 00 <125 mg/dl 2
hour PPBS < 140 mg/dl. CXns\ Impouried Fasting
Glucose F¶v ]d-bpw.
2. FBS >100 <125 mg/dl, 2 hours PPBS > 140 < 199 CXns\
(Impouried Glucose Tolerence) F¶v ]d-bpw.
3. Glycosylated Hb (HbA1c) -5.7 to 6.4
Huj-[-tkh thtWm?
{]talw ]qÀÆm-h-Ø-bn Iïp-]n-Sn-¨mÂ
acp-¶p-IÄ XpS-§p-¶-XmWv `mhn-bnse k¦oÀ
®m-hØ XS-bm³ \Ã-Xv. icn-bmb coXn-bnÂ
`£-W-\n-b-{´-Ww, hymbm-aw, Huj-[-tk-h
Ch-sbms¡ sNbvXm {]talw k¦oÀ®-am-hnÃ
F¶v am{X-aà {]talw CÃm¯ Ah-Ø
-bnte¡pw \o§mw.
Rm³ a[pcw Dt]-£n
-¡mw, hymbmaw sNbvXv
sImÅmw F¶mWv
]d-bm-dp-Å-Xv. Cu Ah
-Ø-bn icn-bmb
\nco-£-W-an-Ãm-sX-bm-bmÂ
]t¯m ]Xn-\t©m hÀjw
sImïv {]tal tcmK
-¯nsâ FÃm-hn[ k¦oÀ
®-X-Ifpw AXm-bXv
I®ns\ _m[n-¡p¶
sdän-t\m-¸-Xn, hr¡sf
_m[n-¡p¶ \yqtdm-¸-Xn,
thZ-\-b-dn-bm-sXbpÅ
lrZ-bm-Lm-Xw,
]£m-LmXw Ch Dïm-Im
-hp-¶-Xm-Wv.
AXp-sIm-ïmWv
{]talw ]qÀÆm-h-Ø-bnÂ
Xs¶ Iïp-]n-Sn-¡p-I-bpw,
thï \nÀt±-i-§fpw
NnIn-Õbpw (Po-hn-X
-ssien amä-§Ä,
Huj-[-tk-h) kzoI-cn-¡p
-Ibpw sN¿-W-sa¶v
]d-bp-¶-Xv.
\½p-sS B-tcm-Kyw | s^{_phcn 2018 87